Published in Clin Neurophysiol on January 13, 2010
RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano (2013) 1.23
Copper chaperone antioxidant protein1 is essential for copper homeostasis. Plant Physiol (2012) 1.09
Photoacoustic sentinel lymph node imaging with self-assembled copper neodecanoate nanoparticles. ACS Nano (2012) 0.92
A Green Synthesis of Carbon Nanoparticle from Honey for Real-Time Photoacoustic Imaging. Nano Res (2013) 0.88
18F-labeling using click cycloadditions. Biomed Res Int (2014) 0.83
Evaluation of trace metal content by ICP-MS using closed vessel microwave digestion in fresh water fish. J Environ Public Health (2014) 0.83
A brief account of nanoparticle contrast agents for photoacoustic imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.78
Risk assessment of heavy metals via consumption of vegetables collected from different supermarkets in La Rochelle, France. Environ Monit Assess (2016) 0.78
Trace elements in dialysis. Pediatr Nephrol (2013) 0.77
Zinc ameliorates copper-induced oxidative stress in developing rice (Oryza sativa L.) seedlings. Protoplasma (2013) 0.77
Detection of Copper(II) Ions Using Glycine on Hydrazine-Adsorbed Gold Nanoparticles via Raman Spectroscopy. Sensors (Basel) (2016) 0.75
Feasibility of proton-activated implantable markers for proton range verification using PET. Phys Med Biol (2013) 0.75
Intestinal Alterations, Basal Hematology, and Biochemical Parameters in Adolescent Rats Fed Different Sources of Dietary Copper. Biol Trace Elem Res (2015) 0.75
The structure of Cu(II) and Hg(II) complexes of bispyrenyl azine revisited. J Mol Model (2017) 0.75
Is cognitive function linked to serum free copper levels? A cohort study in a normal population. Clin Neurophysiol (2010) 1.86
A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J (2003) 1.90
Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res (2002) 1.73
Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin: further support for existence of a new zinc overload syndrome. Arch Neurol (2003) 1.57
XIAP Is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders. Mol Cell (2006) 1.50
Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res (2003) 1.40
Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial. Transl Res (2009) 1.40
Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med (2003) 1.05
Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin II. The denture cream is a primary source of excessive zinc. Neurotoxicology (2009) 1.04
A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg (2008) 1.04
Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther (2003) 1.03
Control of copper status for cancer therapy. Curr Cancer Drug Targets (2005) 0.99
Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia (2002) 0.96
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs (2008) 0.93
Rediscovery of the susceptibility of G6PD deficient persons to methemoglobinemia from oxidant drugs, and to hemolysis from methylene blue. Am J Hematol (2007) 0.91
Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med (2005) 0.87
Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia (2002) 0.86
Effects of tetrathiomolybdate in a mouse model of retinal neovascularization. Invest Ophthalmol Vis Sci (2005) 0.85
Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis. J Pharmacol Exp Ther (2008) 0.85
Toxicity of copper in drinking water. J Toxicol Environ Health B Crit Rev (2010) 0.83
White matter changes in Wilson disease. Arch Neurol (2002) 0.82
Autonomic dysfunction in Wilson's disease. Clin Auton Res (2002) 0.81
Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg (2003) 0.81
Atypical childhood Wilson's disease. Pediatr Neurol (2004) 0.79
Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models. Transl Res (2006) 0.79
Tetrathiomolybdate therapy protects against concanavalin a and carbon tetrachloride hepatic damage in mice. Exp Biol Med (Maywood) (2004) 0.79
Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis. Transl Res (2008) 0.78
Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate. Exp Biol Med (Maywood) (2009) 0.77
Divalent Copper as a Major Triggering Agent in Alzheimer's Disease. J Alzheimers Dis (2015) 0.77
Tetrathiomolybdate is effective in a mouse model of arthritis. J Rheumatol (2006) 0.77
Kayser-Fleischer ring as the presenting sign of Wilson disease. Am J Ophthalmol (2002) 0.76
Prognostic significance of neurologic examination findings in Wilson disease. Parkinsonism Relat Disord (2011) 0.76
Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate. Transl Res (2007) 0.76
Copper status in Alzheimer's disease and other neurodegenerative disorders: genetics, mechanisms, neurophysiology, and therapies. Int J Alzheimers Dis (2011) 0.76
Comment on: "High concentration of zinc in sub-retinal pigment epithelial deposits" (Lengyel et al.) (Exp. Eye Res. 772-780, 84/4, 2007). Exp Eye Res (2008) 0.75
Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease. Neurosci Lett (2009) 0.75
Causes and diagnosis of copper deficiency. Am J Hematol (2008) 0.75
Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc (2002) 0.75
Tetrathiomolybdate is partially protective against hyperglycemia in rodent models of diabetes. Exp Biol Med (Maywood) (2008) 0.75